245 related articles for article (PubMed ID: 22517603)
1. Use of pneumococcal polysaccharide vaccine in children: what is the evidence?
Borrow R; Heath PT; Siegrist CA
Curr Opin Infect Dis; 2012 Jun; 25(3):292-303. PubMed ID: 22517603
[TBL] [Abstract][Full Text] [Related]
2. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
American Academy of Pediatrics Committee on Infectious Diseases
Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
[TBL] [Abstract][Full Text] [Related]
3. Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales.
Ladhani SN; Andrews NJ; Waight P; Borrow R; Slack MP; Miller E
Clin Infect Dis; 2014 Feb; 58(4):517-25. PubMed ID: 24300040
[TBL] [Abstract][Full Text] [Related]
4. [Recommendations for prevention of community-acquired pneumonia with bacteremia as the leading form of invasive pneumococcal infections in the population of people over 50 years of age and risk groups above 19 years of age].
Albrecht P; Antczak A; Hryniewicz W; Skoczyńska A; Radzikowski A; Kedziora-Kornatowska K; Bernatowska E; Stompór T; Grodzicki T; Gyrczuk E; Imiela J; Jedrzejczak W; Windak A
Pol Merkur Lekarski; 2014 Feb; 36(212):79-87. PubMed ID: 24720101
[TBL] [Abstract][Full Text] [Related]
5. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.
Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R
Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924
[TBL] [Abstract][Full Text] [Related]
6. Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: translating research into policy.
Madhi SA; Cohen C; von Gottberg A
Vaccine; 2012 Sep; 30 Suppl 3():C21-7. PubMed ID: 22939016
[TBL] [Abstract][Full Text] [Related]
7. The future of pneumococcal disease prevention.
Rodgers GL; Klugman KP
Vaccine; 2011 Sep; 29 Suppl 3():C43-8. PubMed ID: 21896352
[TBL] [Abstract][Full Text] [Related]
8. Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged ≤59 months---selected U.S. regions, 2010--2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Nov; 60(43):1477-81. PubMed ID: 22048728
[TBL] [Abstract][Full Text] [Related]
9. Early impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in Singapore children, 2005 through 2010.
Thoon KC; Chong CY; Tee NW
Int J Infect Dis; 2012 Mar; 16(3):e209-15. PubMed ID: 22281191
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.
Miernyk KM; Butler JC; Bulkow LR; Singleton RJ; Hennessy TW; Dentinger CM; Peters HV; Knutsen B; Hickel J; Parkinson AJ
Clin Infect Dis; 2009 Jul; 49(2):241-8. PubMed ID: 19522655
[TBL] [Abstract][Full Text] [Related]
12. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.
Fedson DS; Nicolas-Spony L; Klemets P; van der Linden M; Marques A; Salleras L; Samson SI
Expert Rev Vaccines; 2011 Aug; 10(8):1143-67. PubMed ID: 21810065
[TBL] [Abstract][Full Text] [Related]
13. 7-valent pneumococcal conjugate vaccine: new preparation. Prevents rare invasive infections in infants.
Prescrire Int; 2002 Feb; 11(57):7-10. PubMed ID: 11985376
[TBL] [Abstract][Full Text] [Related]
14. Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children.
Paradiso PR
Clin Infect Dis; 2011 May; 52(10):1241-7. PubMed ID: 21507921
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR
Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children.
Muhammad RD; Oza-Frank R; Zell E; Link-Gelles R; Narayan KM; Schaffner W; Thomas A; Lexau C; Bennett NM; Farley MM; Harrison LH; Reingold A; Hadler J; Beall B; Klugman KP; Moore MR
Clin Infect Dis; 2013 Mar; 56(5):e59-67. PubMed ID: 23155149
[TBL] [Abstract][Full Text] [Related]
17. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
Isaacman DJ; McIntosh ED; Reinert RR
Int J Infect Dis; 2010 Mar; 14(3):e197-209. PubMed ID: 19700359
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine.
Miller E; Andrews NJ; Waight PA; Slack MP; George RC
Vaccine; 2011 Nov; 29(49):9127-31. PubMed ID: 21983361
[TBL] [Abstract][Full Text] [Related]
19. 13-valent pneumococcal conjugate vaccine.
Prescrire Int; 2011 Jan; 20(112):5-7, 9. PubMed ID: 21462782
[TBL] [Abstract][Full Text] [Related]
20. Pneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?
Papadatou I; Spoulou V
Clin Vaccine Immunol; 2016 May; 23(5):388-395. PubMed ID: 27009210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]